BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

Navigation und Service

Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)

Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) ZIP, 40 KB, Datei ist nicht barrierefrei